YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
On September 8, Monte Rosa Therapeutics (NASDAQ:GLUE) announced that Novartis (NYSE:NVS), its partner on a VAV1-targeted drug, had dosed the first patient in a Phase 2 trial of MRT-6160 (DDY391) for people with Sjögren's disease. That sing…
All three major US stock indexes fell in late-morning trading Tuesday as oil prices climbed and inve PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Monte Rosa Therapeutics, Inc. Phase 2 study to be conducted in participants with Sjögren's disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive m…
Monte Rosa Therapeutics, Inc. Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2…
Novo Nordisk (NVO) shares tumbled Friday after the Danish pharmaceutical giant said a late-stage tri PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) is one of the best growth stocks under $20 to buy. On May 7, Monte Rosa reported progress across its clinical-stage pipeline, with three programs advancing toward Phase 2 studies. MRT-8102, an NEK…
Monte Rosa Therapeutics, Inc. Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD…
Myriad Genetics (MYGN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items. Thi…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Monte Rosa Therapeutics (NasdaqGS:GLUE) announced a new supply agreement with Johnson & Johnson to evaluate MRT-2359 with ER…
Monte Rosa Therapeutics, Inc. MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretreat…
(RTTNews) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis. - ScinoPharm secures FDA nod for Glatiramer Acet…
Monte Rosa Therapeutics (GLUE [https://seekingalpha.com/symbol/GLUE]) announced a public offering [https://seekingalpha.com/pr/20358925-monte-rosa-therapeutics-announces-pricing-of-300-million-underwritten-public-offering] of 11,125,000 sh…
(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE), a developer of novel molecular glue degrader-based medicines, said that it has priced its underwritten public offering of 11.125 million shares at $24 per share and, in lieu of common stock…
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an…
Monte Rosa Therapeutics GLUE jumped 45.41% following positive interim data from a phase-I study evaluating its immunology and inflammation pipeline candidate, MRT-8102. The candidate is a NEK7-directed molecular glue degrader (“MGD”), bein…
In recent trading, shares of Monte Rosa Therapeutics Inc (Symbol: GLUE) have crossed above the average analyst 12-month target price of $22.70, changing hands for $23.23/share. When a stock reaches the target an analyst has set, the analys…
The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -0.34%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.94%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.06%. March E-mini S&P futures (ESH26) fell -0.36%, and Ma…
Monte Rosa Therapeutics (GLUE) said Wednesday early trial results of its drug candidate, MRT-8102, s PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The S&P 500 Index ($SPX) (SPY) today is up +0.10%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.36%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.34%. March E-mini S&P futures (ESH26) are up +0.10%, and March E-mini Nasdaq f…
The S&P 500 Index ($SPX) (SPY) today is up +0.13%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.10%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.18%. March E-mini S&P futures (ESH26) are up +0.10%, and March E-mini Nasdaq f…
The S&P 500 Index ($SPX) (SPY) today is up +0.13%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.10%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.18%. March E-mini S&P futures (ESH26) are up +0.10%, and March E-mini Nasdaq f…
(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE) announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLR…
(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE) today announced positive interim results from its ongoing Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader in development for NLRP3/IL-1/IL-6 driven inflammatory diseases.…
Monte Rosa Therapeutics, Inc. In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rap…
(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE), a clinical-stage biotechnology company, is scheduled to highlight interim clinical results from the ongoing Phase 1 study of MRT-8102, being developed for the treatment of inflammatory dise…
Monte Rosa Therapeutics surged Tuesday after the biotech said every patients in a prostate cancer study responded to its treatment. Continue Reading
Cementos Pacasmayo (CPAC) said Tuesday that a Swiss company, Holcim, has signed an agreement to acqu PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis Initial data from a Phase…
Monte Rosa Therapeutics, Inc. Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise pa…
Mirum Pharmaceuticals, Inc. (MIRM) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.3 per share a year ago. These figures are adjusted for…
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief…
MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data support the potential of MRT-6160 to addre…
Switzerland-based global healthcare company Novartis (NVS) is gaining momentum this year, thanks to solid pipeline execution, new regulatory wins, high-value license transactions, capital return to shareholders, and positive market sentime…
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is among the best fast money stocks to buy now. During the second quarter, Pallas Capital Advisors acquired a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) through the purchase of 1…
Shares of clinical-stage biotech Monte Rosa Therapeutics GLUE rose 44% on Monday after announcing that it had entered into a collaboration deal with pharma giant Novartis NVS to develop novel molecular glue degraders (MGD) for immune-media…
Monte Rosa Therapeutics GLUE shares soared 44.1% in the last trading session to close at $6.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5% gain over the…